Boundary Capital has announced its latest investment in AB-Polyblok, a revolutionary technology which has the potential to treat, and potentially partially reverse, the effects of Alzheimer’s Disease. AB-Polyblock has a novel potential drug therapy for the treatment of Alzheimer’s Disease. The drug was conceived and developed after independent, private research. Alzheimer’s Disease is the largest…

Boundary Capital is featured in this month’s issue of EIS Magazine discussing the pros and cons of Crowdfunding… Crowdfunding: Where Angels Fear to Tread? Dan Somers, Managing Partner at London-based Boundary Capital Partners, says that crowdfunding is a phenomenon of our age: “Whilst most crowdfunding is debt-based, UK equity crowdfunding (our focus here) rose from…

Boundary Capital Partners LLP is authorised and regulated by the Financial Conduct Authority.
Boundary Capital Partners LLP Reg: OC387581 VAT: 204012873
Registered office: 35 Kingsland Road, London, England, E2 8AA

STAY CONNECTED WITH US: